Long-term follow-up data from a phase 2b trial of Moderna and MSD's mRNA-based vaccine against melanoma, intismeran autogene (mRNA-4157), show an impressive 49% reduction in the risk of disease ...
MSD has fleshed out the results of phase 3 trials of its cholesterol-lowering, oral PCSK9 inhibitor, enlicitide decanoate, showing its efficacy was comparable to that of injectable alternatives. The ...
The NEW 5977B High Efficiency Source (HES) GC/MSD builds on a tradition of providing the most trusted single-quadrupole GC/MS system. The ultra-efficient EI source maximizes the number of ions that ...
The DB-17 GC Column is a (50%-Phenyl)- methylpolysiloxane column of mid polarity. The DB-17 GC Column is excellent for confirmation analysis. The DB-17 GC Column is equivalent to USP Phase G3. Agilent ...
Commvault, a leader in unified resilience at enterprise scale, announced new and forthcoming AI capabilities that help organizations confidently adopt AI while maintaining control over data, agents, ...
About Ginkgo Bioworks Holdings Inc. Ginkgo Bioworks Holdings, Inc. engages in developing biological engineering products and custom microbes. Its platform enables biotechnology applications across ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results